Editor: Atta-ur-Rahman, FRS

Frontiers in Clinical Drug Research- HIV

Volume 4

eBook: US $79 Special Offer (PDF + Printed Copy): US $158
Printed Copy: US $119
Library License: US $316
ISSN: 2468-0397 (Print)
ISSN: 2352-5916 (Online)
ISBN: 978-1-68108-527-2 (Print)
ISBN: 978-1-68108-526-5 (Online)
Year of Publication: 2018
DOI: 10.2174/97816810852651170401

Introduction

Frontiers in Clinical Drug Research – HIV is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of acquired immune deficiency syndrome (AIDS) and other disorders associated with human immunodeficiency virus (HIV) infection. The scope of the book series covers a range of topics including the medicinal chemistry and pharmacology of natural and synthetic drugs employed in the treatment of AIDS (including HAART) and resulting complications, and the virology and immunological study of HIV and related viruses. Frontiers in Clinical Drug Research – HIV is a valuable resource for pharmaceutical scientists, clinicians and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in HIV/AIDS research.

The fourth volume of this series features 5 chapters that cover these topics:

  • -Design and Synthesis of HIV-1 Protease Inhibitors
  • -Potential Magnetic Nanotherapeutics for Management of neuroAIDS
  • -Syntheses of FDA Approved Integrase Inhibitor HIV Drugs and Improved Manufacturing using Flow Processing
  • -The Development and Clinical Progress on Chemokine Receptor-Based HIV Entry Inhibitors
  • -Sexually Transmitted Co-infections in Persons Living with HIV

Preface

The book series Frontiers in Clinical Drug Research-HIV presents important recent developments in the form of cutting edge reviews written by eminent authorities in the field. The chapters in this 4th volume are mainly focused on different types of HIV-1 inhibitors (integrase inhibitors, protease inhibitors, entry inhibitors, etc.), magnetic nanotherapeutics, and sexually transmitted co-infections.

Alluri and Ganguly in Chapter 1 discuss the design and synthesis of HIV-1 protease inhibitors based on a cyclic sulfonamide core structure. Sagar et al., in chapter 2 discuss the importance of magnetic nanocarriers for delivering therapeutics which can exert changes at genetic levels. Chapter 3 by Watts et al., describes the synthesis of currently FDA approved integrase inhibitor drugs and other HIV drugs developed through flow technology.

Chapter 4 by Yi-Qun Kuang focuses on the development and clinical progress on chemokine receptor-based HIV entry inhibitors. Cobucci et al., in chapter 5, discuss the most prevalent co-infections found in HIV carriers and their epidemiology, clinical features and evidence-based treatments.

I am grateful to all the eminent scientists for their excellent contributions. I also express my gratitude to the editorial staff, particularly Mr. Mahmood Alam (Director Publication), Mr. Shehzad Naqvi (Editorial Manager Publications) and Ms. Fariya Zulfiqar (Manager Publications) for their hard work and persistent efforts.


Prof. Atta-ur-Rahman, FRS
Kings College
University of Cambridge
Cambridge
UK

RELATED BOOKS

.Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features.
.Frontiers in Clinical Drug Research-Anti-Infectives.
.Ricin Toxin.
.Tuberculosis: A Clinical Practice Guide  .
.The COVID-19 Pandemic: Epidemiology, Molecular Biology and Therapy.
.Frontiers in Clinical Drug Research- HIV.
.21 Century Challenges in Antimicrobial Therapy and Stewardship.